Essen said that the new 25,000 sq ft facility provides Essen the space to accommodate the expansion of both their instrumentation and contract service business units.
Recently, Essen has expanded its instrumentation-based business model to include contract services, assembling a team of senior scientists who have successfully managed and driven drug discovery projects at major pharmaceutical companies. The combination of drug discovery and instrumentation experience makes Essen a provider of life science research tools and services.
Kirk Schroeder, president and CEO, said: “Our name change to Essen BioScience better reflects our current global business model. We’ve traditionally been known for innovative life science instrumentation, however our corporate strength is founded in developing novel assays to advance drug discovery. Via our growing service model, we can bring our assays and expertise to more customers.
“We are very proud of our new facility. This investment reflects our commitment to our customers, our employees and to generating jobs in Southeast Michigan.”
Essen BioScience delivers technologies for the life science industry including products such as FLIPR, IonWorks and IncuCyte.